07:00 , May 9, 2016 |  BC Week In Review  |  Company News

Novogen, Yale University deal

Novogen said it ceased funding and will wind down operations of its 2013 CanTx Inc. JV with the university as the biotech plans to move Cantrixil in to Phase I trials, which are expected to...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Novogen, Yale University preclinical data

In a mouse model of ovarian cancer, 100 mg/kg intraperitoneal Cantrixil for 17 days significantly reduced tumor burden by >90% vs. vehicle-treated controls (p<0.01). Additionally, Cantrixil plus cisplatin led to significantly greater reductions in tumor...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Cantrixil regulatory update

FDA granted Orphan Drug designation to Novogen’s Cantrixil to treat ovarian cancer. Cantrixil is a cyclodextrin envelope containing cytotoxic TRXE-002 , a dimer of 2 benzopyran rings called a super-benzopyran, designed for intra-peritoneal use. It...